The Bruton ’s tyrosine kinase inhibitor acalabrutinib protects from anaphylaxis in a humanized mouse model

There is an unmet need for therapies that can prevent anaphylaxis. Acalabrutinib is a well-tolerated, FDA approved drug for leukemia that targets Bruton ’s tyrosine kinase (BTK), an enzyme also thought to be essential for IgE receptor signaling in human mast cells and basophils. We tested the hypothesis that acalabrutinib administration would prevent anaphylaxis in a humanized mouse model.

Source: Journal of Allergy and Clinical Immunology - February 1, 2019 Category: Allergy & Immunology Authors: Melanie C. Dispenza, Rebecca A. Krier-Burris, Bruce S. Bochner Source Type: research